Bragg Financial Advisors Inc Increases Position in Eli Lilly and Company (NYSE:LLY)

Bragg Financial Advisors Inc increased its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 3.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,013 shares of the company's stock after purchasing an additional 397 shares during the quarter. Bragg Financial Advisors Inc's holdings in Eli Lilly and Company were worth $9,274,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Highline Wealth Partners LLC grew its holdings in shares of Eli Lilly and Company by 80.0% in the 4th quarter. Highline Wealth Partners LLC now owns 45 shares of the company's stock worth $35,000 after acquiring an additional 20 shares during the period. FPC Investment Advisory Inc. boosted its position in Eli Lilly and Company by 358.3% during the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after purchasing an additional 43 shares in the last quarter. Prudent Man Investment Management Inc. acquired a new stake in Eli Lilly and Company in the fourth quarter valued at $48,000. Compass Financial Services Inc acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth $50,000. Finally, Fiduciary Advisors Inc. purchased a new stake in shares of Eli Lilly and Company in the 4th quarter worth about $58,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Morgan Stanley cut their target price on shares of Eli Lilly and Company from $1,146.00 to $1,124.00 and set an "overweight" rating for the company in a research report on Wednesday, April 9th. Berenberg Bank set a $970.00 target price on Eli Lilly and Company in a report on Thursday, January 16th. StockNews.com raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Friday, February 7th. Guggenheim dropped their price objective on Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating for the company in a research report on Monday. Finally, Truist Financial upped their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a report on Monday, February 3rd. Two analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of "Moderate Buy" and a consensus price target of $1,012.00.

Remove Ads

Insider Transactions at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 0.14% of the company's stock.

Eli Lilly and Company Trading Down 2.9 %

NYSE LLY traded down $22.33 during mid-day trading on Wednesday, hitting $734.85. The company's stock had a trading volume of 3,301,963 shares, compared to its average volume of 3,389,995. The firm has a market capitalization of $696.76 billion, a P/E ratio of 62.75, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The stock's fifty day simple moving average is $832.96 and its two-hundred day simple moving average is $821.54.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.